CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel adoptive immune cell therapy for metastatic melanoma by inhibiting NR2F6, an immune checkpoint. The approach enhances T cell function and aims to improve patient responses to existing immunotherapies, potentially transforming treatment outcomes for this aggressive skin cancer.
Melanoma cases and deaths are expected to increase in the coming years, representing a significant burden for the European economy and healthcare system.
Metastatic melanoma (MM) is the most serious form of skin cancer and is characterised by uncontrolled metastatic spread of melanocytes to distant sites.
Although standard treatments exist, significant clinical challenges remain, resulting in limited response and high MM recurrence rates.
As a result of these limited treatment options, the quali…
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
